Biosimilar and Biologics Market

How big is the Biosimilar and Biologics Market in 2026?

USD 604.4 million in 2026, reaching USD 1,257.3 million by 2036 at a 7.6% CAGR

The biosimilar and biologics market is estimated at USD 604.4 million in 2026 and is forecast to reach USD 1,257.3 million by 2036 at a 7.6% CAGR. Demand is shaped by oncology and autoimmune disease treatment, where monoclonal antibody and their biosimilars expand patient access. Monoclonal antibody account for 32.4% of drug class demand in 2026, while bacterial cells lead source at 45.6%.

The market was valued at USD 561.7 million in 2025. Growth reflects biosimilar entry expanding access to high-cost biologics and rising oncology and autoimmune treatment. Demand is shaped by hospitals and specialty pharmacies dispensing reference biologics and biosimilars as patent expiries widen the competitive landscape.

The biosimilar and biologics market is expanding as biosimilar entry widens access to high-cost reference biologics. Buyers judge products through efficacy, immunogenicity, and cost. sourcing centers on hospital pharmacy and specialty channels.

Metric	Value
2025 Market Size	USD 561.7 million
2026 Market Size	USD 604.4 million
2036 Market Size	USD 1,257.3 million
Forecast CAGR (2026 to 2036)	7.6%
Drug Class Focus	Monoclonal Antibody
Monoclonal Antibody Share (2026)	32.4%
Source Focus	Bacterial Cells
Bacterial Cells Share (2026)	45.6%
Fastest-growing Country	China
Key Countries	USA, Germany, France, UK

Summary of the Biosimilar and Biologics Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Demand is driven by oncology and autoimmune treatment, with biosimilar entry after patent expiries widening access to costly biologics. Hospitals adopt monoclonal antibody reference biologics and biosimilars for oncology treatment, expanding patient access as biosimilars lower cost. Autoimmune disease treatment drives demand for biologics and biosimilars across rheumatology and gastroenterology. Biosimilar entry following patent expiries widens access to high-cost biologics across therapy areas.
Product and Segment View	Monoclonal antibody biologics and bacterial-cell expression lead the mix, with oncology the largest application. Monoclonal antibody account for 32.4% of Drug class demand, anchored by oncology and autoimmune indications. Bacterial cells lead source at 45.6% share as established expression systems support recombinant biologic production. Oncology leads application as it represents the largest biologic and biosimilar treatment area.
Geography and Competitive Outlook	China leads growth on biosimilar manufacturing and access programs, while majors compete on manufacturing scale and immunogenicity data. China is forecast to record 8.8% CAGR by 2036 due to biosimilar manufacturing and access programs. Spain and the USA follow at 7.4% and 5.9% CAGR as biosimilar adoption and reimbursement expand. Pfizer and Roche compete with AbbVie through biologic and biosimilar portfolios. Manufacturing scale and immunogenicity data separate suppliers.
Analyst Opinion	Producers pairing reliable biologic manufacturing with cost-competitive biosimilars and strong immunogenicity data will lead as patents expire. Producers that combine reliable biologic manufacturing with cost-competitive biosimilars and strong immunogenicity data will lead as patent expiries widen access across oncology and autoimmune disease. Adoption is increasing due to biosimilar entry expanding access to high-cost reference biologics. - Anurag Sharma, Principal Consultant at Future Market Insights

Why is the Biosimilar and Biologics Market growing?

Rising Monoclonal Antibody and Bacterial Cell-sourced biologic demand in oncology and autoimmune treatment

• Sustained sourcing of monoclonal antibody reference biologics and biosimilars is shaped by hospitals treating oncology and autoimmune disease.
• China is leading the way with growth of 8.8%, driven by biosimilar manufacturing, access programs, and rising biologic adoption.
• The source segment is led by Bacterial Cells at 45.6% share, supported by established expression systems for recombinant production.

Demand is rising because biologics treat oncology, autoimmune, and rare diseases where small-molecule alternatives are limited. Adoption is increasing due to biosimilar entry following patent expiries, which lowers cost and widens access to high-cost monoclonal antibody biologics across hospital and specialty pharmacy channels.

How is the Biosimilar and Biologics Market segmented?

By Drug Class, Source, Application, Manufacturing Type and Distribution Channel

• Monoclonal antibody are projected to lead drug class demand with 32.4% share in 2026 due to oncology and autoimmune use.
• Bacterial cells are expected to lead source with 45.6% share in 2026 as established expression systems support production.
• Hospital pharmacies are forecast to lead distribution channel as biologics are hospital-administered.

Why do monoclonal antibody reference biologics lead the Biosimilar and Biologics Market?

• Monoclonal antibody are expected to hold 32.4% share in 2026 because they treat high-burden oncology and autoimmune disease.
• Their biosimilars expand access as patent expiries open competition, sustaining the drug class.

How big is the source segment in the Biosimilar and Biologics Market?

• Bacterial cells hold 45.6% share, led by established recombinant expression
• Bacterial cells form the leading source at 45.6% share, anchored by established recombinant expression systems.
• Yeast and mammalian cell sources follow where complex glycosylation is required.

Which Application leads the market?

• Oncology leads application as it represents the largest biologic and biosimilar treatment area.
• Autoimmune disease and rare disease follow, driving monoclonal antibody and fusion protein demand.

Which manufacturing type leads procurement?

• In house manufacturing leads as established producers retain biologic production capacity.
• Contract and hybrid manufacturing follow as biosimilar developers outsource capacity.

Which distribution channel leads the market?

• Hospital pharmacies lead distribution as biologics are hospital-administered and monitored.
• Specialty and retail pharmacies follow as self-administered biologics extend to outpatient care.

What drives and restrains the Biosimilar and Biologics Market?

Driven by biosimilar access expansion and oncology demand; restrained by manufacturing complexity and immunogenicity barriers

Biosimilar entry and oncology demand support growth while biologic manufacturing complexity and immunogenicity concerns limit faster substitution.

• Driver: Hospitals treating oncology and autoimmune disease adopt monoclonal antibody biologics and biosimilars, with biosimilar entry following patent expiries lowering cost and expanding patient access.
• Restraint: Substitution is constrained by biologic manufacturing complexity and immunogenicity concerns that require extensive comparability data, slowing biosimilar uptake in some therapy areas.
• Opportunity: Expanding biosimilar portfolios across oncology and autoimmune indications can widen access as more reference biologics reach patent expiry.

Biosimilar entry is lifting access to high-cost biologics as hospitals treat oncology and autoimmune disease. Reference biologics anchor the market while biosimilars expand access through cost competition.

The market is led by structural demand from hospital-administered biologic therapy. Monoclonal antibody biologics remain the leading class, while biosimilars expand access. Constraints include manufacturing complexity, immunogenicity concerns, and regulatory comparability requirements.

Which factors support expansion in the Biosimilar and Biologics Market?

Biologic adoption and biosimilar access support market value across hospital and specialty channels

• Market value is supported by reference biologic adoption before biosimilars expand volume access.
• Product pricing reflects manufacturing scale and immunogenicity data before competition affects realization.
• Hospitals compare efficacy, immunogenicity, and cost before adopting a biosimilar.

Which countries are growing fastest in the Biosimilar and Biologics Market?

Country	CAGR
China	8.8%
Spain	7.4%
USA	5.9%
Germany	4.6%
Japan	4.0%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in the Biosimilar and Biologics Market?

The global biosimilar and biologics market is projected to expand at 7.6% from 2026 to 2036. The study covers more than 30 countries, and the primary markets are listed below.

• China is forecast to record 8.8% CAGR by 2036 as biosimilar manufacturing and access programs expand.
• Spain is expected to expand at 7.4% CAGR through 2036 as biosimilar adoption rises across the health system.
• The USA is estimated to grow at 5.9% CAGR by 2036 as biosimilar reimbursement and uptake widen.
• Germany is projected to rise at 4.6% CAGR through 2036 as EU biosimilar policy shapes adoption.
• Japan is forecast to post 4.0% CAGR by 2036 as biosimilar uptake grows under established biologic use.

Who are the leading companies in the Biosimilar and Biologics Market?

Pfizer, Hoffmann-La Roche, AbbVie, Novartis, and Merck & Co.

Pfizer and Hoffmann-La Roche compete through biologic and biosimilar portfolio breadth. Manufacturing scale remains a further point of differentiation. AbbVie and Novartis compete on reference biologics and biosimilars, while Merck & Co. and Amgen hold positions in biologic production. These overlap with broader oncology and autoimmune buying paths.

Buyers compare products on efficacy, immunogenicity, and cost. Hospitals standardize on biologics and biosimilars with strong comparability data and reliable supply. Health systems favor cost-competitive biosimilars as patent expiries widen competition across therapy areas.

Who are the key players in the Biosimilar and Biologics Market?

Key global companies leading the Biosimilar and Biologics Market include:

• Pfizer, Hoffmann-La Roche, and AbbVie maintain leading positions through biologic and biosimilar portfolios, manufacturing scale, and hospital relationships across global markets.
• Established pharmaceutical players such as Novartis, Merck & Co., and Amgen compete through reference biologics and biosimilars.
• Specialist and emerging producers such as Biocon, Intas Pharmaceuticals, and Viatris target cost-competitive biosimilars to establish positions and scale.

How do top Biosimilar and Biologics Market companies compare?

Pfizer and Roche lead on scale; AbbVie also has a global footprint, while Biocon and Intas are more biosimilar-concentrated.

Company	Portfolio Breadth	Manufacturing Scale	Distribution Scale	Geographic Footprint
Pfizer	High	High	Strong	Global
Hoffmann-La Roche	High	High	Strong	Global
AbbVie	High	Moderate	Strong	Global
Novartis	High	High	Strong	Global
Amgen	Moderate	High	Strong	Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in the Biosimilar and Biologics Market

• In October 2025, the FDA issued draft guidance proposing to simplify biosimilarity studies and reduce comparative clinical efficacy testing, alongside a separate initiative easing interchangeability designation. Lower development cost and shorter timelines widen the range of biologics worth targeting. Regulatory clarity supports developers evaluating programme economics before committing to 351(k) pathway investment. 

• In December 2025, Amneal Pharmaceuticals and mAbxience, a Fresenius Kabi majority-owned group, received FDA approval for denosumab biosimilars Boncresa and Oziltus, referencing Prolia and Xgeva, with Amneal targeting six biosimilars across eight presentations by 2027. Multiple approvals in a single reference class intensify price competition in bone health. Portfolio evidence supports payers modelling formulary savings before renegotiating biologic contracts. 

• In March 2026, Sandoz and Samsung Bioepis signed a licensing, development and commercialisation agreement covering up to five biosimilar assets, beginning with SB36 referencing Entyvio (vedolizumab), extending Sandoz's pipeline toward 32 assets. Early-stage asset partnering secures positions ahead of the coming patent cliff. Pipeline commitment supports health systems forecasting biosimilar availability before planning long-range sourcing. 

Key Players in the Biosimilar and Biologics Market

Global Biologic Leaders

• Pfizer Inc.
• Hoffmann-La Roche AG
• AbbVie Inc.
• Novartis AG

Established Biologic Producers

• Merck & Co., Inc.
• Amgen Inc.
• Bristol Myers Squibb Co.
• GSK plc
• AstraZeneca

Biosimilar Specialists

• Biocon Limited
• Intas Pharmaceuticals Limited
• Viatris Inc.
• Serum Institute of India

Biosimilar and Biologics Market - Scope & Definition

Attribute	Detail
Market Definition	Biologic medicines and their biosimilars used to treat oncology, autoimmune, and other diseases, spanning drug classes, expression sources, and manufacturing types
Functions Covered	Biologic therapy, biosimilar substitution, recombinant production, and disease treatment across therapy areas
Applications Covered	Oncology, autoimmune disease, infectious disease, rare disease, cardiovascular, and hematological disorders
End-Use Industries	Hospitals, specialty clinics, and pharmacy channels
Inclusions	Monoclonal antibody biologics, vaccines, recombinant insulin, growth factors, immune modulators, fusion proteins, and biosimilars
Exclusions	Small-molecule drugs, non-biologic therapies, and diagnostic biologics outside treatment use

Biosimilar and Biologics Market - Research Methodology

Method	Description
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, sourcing teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing & Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

What does the Biosimilar and Biologics Market report cover?

2021 to 2025 history and 2026 to 2036 forecasts across all segments and 30+ countries

Parameter	Details
Forecast period	2026 to 2036
Historical period	2021 to 2025
Quantitative unit	Value in USD million
By Drug class	Monoclonal Antibody , Vaccines, Recombinant Insulin, Growth Factors, Immune Modulators, Fusion Protein
By Source	Bacterial Cells, Yeast Cells, Plant Cells, Animal Cells, Other Sources
By Application	Oncology, Autoimmune Disease, Infectious Diseases, Rare Disease, Cardiovascular Disorders, Hematological Disorders
By Manufacturing type	In House Manufacturing, Contract Manufacturing, Hybrid Manufacturing
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Mail Order Pharmacies
Regions covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	USA, China, Spain, Germany, Japan, and other major markets
Key companies profiled	Pfizer, Hoffmann-La Roche, AbbVie, Novartis, Merck & Co., Amgen, Biocon, Intas Pharmaceuticals, Viatris, Serum Institute of India
Approach	Bottom-up adoption-based approach using drug-class uptake, source mix, application demand, and supplier disclosures

Market Segmentation Analysis

Biosimilar and Biologics Market Segmented by Drug Class:

• Monoclonal Antibody
  • Reference Biologics
  • Biosimilar Monoclonal Antibodies
  • Next Generation Antibodies
• Vaccines
  • Routine Vaccines
  • Specialty Vaccines
• Recombinant Insulin
  • Insulin Products
  • Erythropoietin Products
  • Growth Hormones
• Growth Factors
• Immune Modulators
• Fusion Protein
• Erythoprotein
• Therapeutic Enzymes
• Interferons
• Colony Stimulation Factors
• Oligonucleotides

Biosimilar and Biologics Market Segmented by Source:

• Bacterial Cells
• Yeast Cells
• Plant Cells
• Animal Cells
• Other Sources

Biosimilar and Biologics Market Segmented by Application:

• Oncology
  • Solid Tumor Treatments
    • Breast Cancer Biologics
    • Lung Cancer Biologics
  • Hematology Oncology
    • Lymphoma Treatments
    • Leukemia Treatments
• Autoimmune Disease
  • Rheumatology
    • Rheumatoid Arthritis Therapies
    • Ankylosing Spondylitis Therapies
  • Gastroenterology
    • Crohn Disease Therapies
    • Ulcerative Colitis Therapies
  • Dermatology
    • Psoriasis Therapies
    • Atopic Disease Therapies
• Infectious Diseases
• Rare Disease
  • Enzyme Replacement Therapies
  • Genetic Disorder Therapies
• Cardiovascular Disorders
• Hematological Disorders
  • Anemia Management
  • Bleeding Disorders
• Other Application

Biosimilar and Biologics Market Segmented by Manufacturing Type:

• In House Manufacturing
  • Integrated Biologics Plants
    • Cell Culture Production
    • Fill Finish Operations
  • Captive Biosimilar Facilities
    • Dedicated Scale Up Sites
    • Quality Controlled Networks
• Contract Manufacturing
  • CDMO Production
    • Mammalian Cell Capacity
    • Microbial Production Capacity
  • Fill Finish Outsourcing
    • Sterile Injectables Packaging
    • Regional Supply Support
• Hybrid Manufacturing
  • Core In House API
    • Strategic Control Model
    • High Value Molecule Focus
  • Outsourced Final Packaging
    • Flexible Market Entry
    • Multi Region Distribution

Biosimilar and Biologics Market Segmented by Distribution Channel:

• Hospital Pharmacies
  • Inpatient Supply
    • Cold Chain Storage Supply
    • Infusion Drug Dispensing
  • Tender Procurement Channels
    • Bulk Public Contracts
    • Group Purchasing Supply
• Retail Pharmacies
  • Chain Pharmacies
    • Insulin and Self Injectables
    • Urban Access Stores
  • Independent Pharmacies
    • Community Specialty Access
    • Prescription Counseling
• Online Pharmacies
  • E Prescription Platforms
    • Home Delivery Cold Chain
    • Refill Subscription Models
  • Specialty E Commerce
    • Remote Patient Access
    • Digital Support Programs
• Specialty Pharmacies
  • High Cost Therapy Management
    • Prior Authorization Support
    • Patient Adherence Services
  • Manufacturer Hubs
    • Copay Assistance Programs
    • Nurse Education Services
• Mail Order Pharmacies

Biosimilar and Biologics Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• World Health Organization. (2025, October). Global report on biologic and biosimilar medicine access.
• Organisation for Economic Co-operation and Development. (2025, November). Health at a Glance: biologic therapy uptake.
• USA Food and Drug Administration. (2026, February 12). Biosimilar approvals and interchangeability guidance.
• European Medicines Agency. (2025, December 10). Biosimilar assessment and comparability reports.
• National Medical Products Administration of China. (2025, September). Biosimilar approval and access bulletin.
• Pfizer Inc. (2026, February 4). 2025 annual report and biopharmaceutical portfolio overview.
• Hoffmann-La Roche AG. (2026, February 1). 2025 results and biologics franchise update.

This bibliography is provided for reader reference and is not exhaustive.

This Report Answers

• Market size estimates for 2026 and forecasts through 2036 for the Biosimilar and Biologics Market.
• Analysis of drug-class demand across monoclonal antibody biologics and biosimilars.
• Country-level growth analysis covering China and Spain with USA, Germany and Japan outlooks.
• Evaluation of company positioning across Pfizer and Roche with AbbVie, Novartis and Amgen.
• Assessment of drivers and restraints with procurement patterns across hospital and specialty channels.